NACmart-AB Tablet

Acetylcysteine

600 mg + Acebrophylline 100 mg

A Comprehensive Pharmacological Approach to Productive Airway Disease

Respiratory disorders associated with mucus retention and airway obstruction require therapies that address secretion clearance, airway tone, and inflammation simultaneously. NACmart-AB Tablet combines two well-studied respiratory agents to provide a multi-mechanistic approach to airway management.

Composition

Each tablet contains:

• Acetylcysteine IP – 600 mg

• Acebrophylline – 100 mg

• Excipients q.s.

Available in Alu-Alu blister pack of 10 tablets, ensuring enhanced moisture protection and stability.

Pharmacodynamic Profile

Acetylcysteine

Acetylcysteine acts primarily as a mucolytic and antioxidant.

Mechanism of action:

• Cleaves disulfide bonds in mucoproteins → reduces mucus viscosity

• Enhances expectoration and mucociliary transport

• Replenishes intracellular glutathione levels

• Reduces oxidative stress–mediated lung injury

Clinical effect:
Improves airway clearance, reduces chest congestion, and supports lung tissue protection in chronic inflammatory states.

Acebrophylline

Acebrophylline is a xanthine derivative with bronchodilator, mucoregulator, and anti-inflammatory properties.

Mechanism of action:

• Inhibits phosphodiesterase → increases cAMP → bronchodilation

• Improves surfactant secretion and mucociliary clearance

• Reduces inflammatory cytokine release

• Decreases bronchial hyper-responsiveness

Clinical effect:
Enhances airflow, reduces airway resistance, and stabilizes respiratory function.

Combined Pharmacodynamic Advantage

The combination targets multiple disease pathways:

• Liquefies and removes airway secretions

• Relaxes bronchial smooth muscle

• Reduces inflammatory activity

• Protects lung epithelium from oxidative injury

This integrated action makes the therapy suitable for chronic productive respiratory disorders.

Pharmacokinetics

Acetylcysteine

• Absorption: Rapidly absorbed after oral administration

• Bioavailability: Moderate due to first-pass metabolism

• Distribution: Widely distributed in lung tissue and bronchial secretions

• Metabolism: Hepatic metabolism to cysteine and glutathione precursors

• Elimination half-life: Approximately 5–6 hours

• Excretion: Primarily renal

Acebrophylline

• Absorption: Well absorbed orally

• Peak plasma concentration: Achieved within 1–2 hours

• Distribution: Good pulmonary tissue penetration

• Metabolism: Hepatic metabolism

• Elimination half-life: Around 8–12 hours

• Excretion: Mainly via urine

The pharmacokinetic properties of both drugs allow once- or twice-daily dosing for sustained respiratory benefit.

Therapeutic Indications

NACmart-AB may be prescribed in:

• Chronic bronchitis

• Chronic obstructive pulmonary disease (COPD)

• Bronchial asthma with mucus retention

• Bronchiectasis

• Post-infective productive cough

• Smoker’s cough with secretion

Adverse Drug Reactions

The combination is generally well tolerated.

Common mild reactions

• Gastric irritation or dyspepsia

• Nausea

• Headache

• Mild dizziness

Less common

• Palpitations (xanthine-related effect)

• Skin rash or hypersensitivity

• Loose stools

Rare but notable

• Exacerbation of peptic ulcer symptoms

• Bronchospasm in hypersensitive individuals

Patients should be advised to report persistent gastrointestinal symptoms or allergic manifestations.

Precautions and Warnings

• Use cautiously in patients with peptic ulcer disease

• Monitor in severe hepatic impairment

• Dose adjustment may be required in renal dysfunction

• Avoid concomitant antitussives that suppress sputum clearance

• Use under medical supervision in elderly and cardiac patients

Drug Interactions

• Additive effect with other bronchodilators

• Possible interaction with theophylline-containing therapy

• Antitussives may reduce therapeutic mucus clearance

Dosage and Administration

Usually taken after meals, once or twice daily as directed by the physician. Adequate hydration supports mucolytic action.

Conclusion

Chronic respiratory diseases often involve multiple pathological processes. By combining mucolytic, bronchodilator, antioxidant, and anti-inflammatory properties, NACmart-AB Tablet provides a rational pharmacological option for improving airway clearance and breathing comfort in patients with productive airway disease.